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INTRODUCTION 
 Clostridium difficile (C. difficile) is the leading cause of healthcare-associated infections 
in the United States. According to recent data from the Center of Disease Control (CDC’s) 
National Healthcare Safety Network, 3644 U.S. hospitals reported 98,448 cases of hospital-
onset clostridium difficile infections (CDI), with over 80% hospitals having one or more cases 
(Gould & McDonald, 2009). In 2014, a national prevalence survey found that Clostridium 
difficile was not only the most commonly reported pathogen, but caused 12% of health care-
associated infections in the United States (Magill et al., 2014). Each year, an estimated 14,000 
deaths are attributed to CDI, resulting in a mortality rate of 6.9% at 30 days after diagnosis and 
16.7% at one year (E. Dubberke, 2012; Erik Dubberke et al., 2008). Consequently, it cost an 
estimated $5,000 - $7,000 in healthcare expenses per case, totaling at an estimated $1 billion 
to $1.6 billion dollars annually (Scott, 2009). Due to this epidemic, multiple hospitals across the 
United States have implemented prevention collaboratives in an effort to decrease the rate of 
CDI (Control & Prevention, 2015). As a result, the CDC indicated several of the participating 
hospitals observed an overall decrease in the incidence of CDI. 
C. difficile is a gram positive anaerobic bacterium that causes potentially deadly 
diarrhea, which can be spread in healthcare settings (Kelly & LaMont, 2008; Paredes, Alsaker, & 
Papoutsakis, 2005). Most cases of CDI occur in patients previously exposed to prolonged cycles 
of antibiotics. As a patient takes antibiotics, their microflora, or “good bacteria”, which protect 
against infections are decreased for several months. During this time, C. difficile in the 
vegetative stage can invade the patient’s intestines, colonize, and causes infection (Kuipers & 
Surawicz, 2008; Seekatz & Young, 2014). Most often C. difficile is contracted nosocomially, but 
can also be transferred from person to person through the fecal-oral route (Kyne, Farrell, & 
Kelly, 2001; Tabaqchali & Wilks, 1992). In most cases of antibiotic associated 
pseudomembranous colitis, C. difficile is the primary cause (Bartlett, 1994).  CDIs are difficult to 
treat because of its ability to form endospores, which are resistant to extreme conditions 
including high temperatures, ultraviolet light, antiseptics, and antibiotics.  They can survive in 
the environment for up to two years (Underwood et al., 2009). Due to this resistance, spores 
can remain in a patient’s gastrointestinal tract for extended periods of time, causing recurrent 
CDIs following eradication of vegetative C. difficile. 
Most vegetative bacterial cells are killed by the acidic environment in the stomach. 
However, C. difficile spores can survive this environment, allowing passage to the intestines. An 
increased incidence of CDI in some studies has been correlated with the use of proton pump 
inhibitors, particularly in combination with antibiotics (Dial, Delaney, Barkun, & Suissa, 2005; 
Dial, Delaney, Schneider, & Suissa, 2006). There is evidence that proton pump inhibitors can 
affect the microbiota of the gastrointestinal tract both by lowering the environmental pH and 
by a direct effect of the drug on bacteria (Altman et al., 2008) (Vesper et al., 2009).  
In vitro studies suggest that the germination and outgrowth of the C. difficile endospore 
are dependent on the exposure of specific bile acids, primarily taurocholate in combination 
with glycine (Heeg, Burns, Cartman, & Minton, 2012; Sorg & Sonenshein, 2010). The 
dependency of C. difficile spore germination with bile acids is a direct result of their ability to 
utilize sugars and undergo the metabolic process of amino acid fermentation to create ATP as a 
source of energy (Jackson, Calos, Myers, & Self, 2006). A polysaccharide capsule discourages 
phagocytosis of the C. difficile bacterium, while flagella facilitate its movement. As C. difficile 
colonize, the bacterium adheres to the colonic epithelium. By prioritizing growth over toxin 
production, C. difficile can exponentially grow and colonize dramatically before producing 
detectable toxins (Dupuy & Sonenshein, 1998). This can make identifying patients with a 
progressing CDI quite difficult when using toxin based screening.  
As C. difficile growth slows, production of its two virulence factors, enterotoxin (toxin A) 
and cytotoxin (toxin B), as well hydrolytic enzymes begins.  If untreated, the production of 
toxins A and B result in increased vascular permeability, neutrophil and monocyte recruitment, 
production of tumor necrosis factor-alpha and pro-inflammatory interleukins, opening of 
epithelial cell junctions, and eventually epithelial cell apoptosis. The production of hydrolytic 
enzymes leads to connective tissue degradation, pseudomembrane formation, watery diarrhea, 
and eventually colitis (Weston, 2008). 
 The most common treatments for CDI are vancomycin and metronidazole, which 
eradicate C. difficile’s cell wall inducing cell death (Kuipers & Surawicz, 2008; Zheng et al., 
2007). However, these treatments are only viable for vegetative C. difficile, having little to no 
effect on C. Difficile spores. When standard treatment has failed, one strategy that has been 
shown to be effective in eradicating C. difficile in patients with recurrent CDIs is intestinal 
microbiota transplantation (IMT), also known as the fecal transplant. IMT is an alternative 
therapy for CDI patients that involve infusing intestinal microorganisms (in a suspension of a 
healthy donor stool) into the intestine of an infected patient (Gough, Shaikh, & Manges, 2011). 
This allows for the restoration of a healthy microbiota, which theoretically will overpower the 
colonizing C. difficile. In a systematic literature review study of IMT treatment for recurrent CDI, 
IMT was shown to be highly effective in eradicating C. difficile, with resolution in 92% of 
patients (Gough et al., 2011).   
One hospital method that has been shown to be highly effective in reducing the 
deterioration of patient’s microflora, and in turn C. difficile infections, is the implementation of 
an antibiotic stewardship program (D. N. Gerding, Muto, & Owens, 2008). For example, the use 
of high-risk antibiotics (second-generation cephalosporins, third-generation cephalosporins, 
fluoroquinolones and clindamycin) has been positively correlated with a significant decrease in 
the CDI incident rate by 0.0047/100 bed-days per month (Mamoon A. Aldeyab et al., 2012). 
Further decreases were observed with implementing stewardship with medium-risk antibiotics 
(amoxicillin/clavulanic acid and macrolides).  
Our goal in this study is to determine if there was a causal relationship between the use 
of hospital hand hygiene, the implementation of more sensitive PCR-based testing and the 
promotion of an antibiotic stewardship program on the rate of hospital-associated C. difficile 
infection (CDI).    
METHODS  
Study Design 
 A four-year retrospective study that compared the relationship between hospital hand 
hygiene, CDI test sensitivity and an antibiotic stewardship program to hospital-associated CDI 
rates was conducted from July, 2011 through September, 2015 at Southern Ohio Medical 
Center (SOMC). CDI rates were gathered at monthly intervals.  
Hospital 
  SOMC is a 222-bed not-for-profit hospital providing emergency and surgical care to the 
residents of Ohio, with an average annual census of 13,000 patients admitted during the data 
acquisition period. 
C. Difficile Prevention Strategy 
Three primary prevention strategies were implemented in this study:  
The first is the hand hygiene policy implemented in 2011 to prevent hospital-associated 
infections. In compliance with CDC, all employees were required to apply either soap and water 
or alcohol-based hand gel immediately before entering and immediately upon exiting a 
patient’s room using readily accessible hand hygiene stations. Hand hygiene compliance was 
monitored and timely feedback was given to healthcare personnel if lapses in protocol were 
observed. Although alcohol-based hand gels are efficient in the prevention of MRSA, they are 
not efficient in eradicating C. difficile spores (Oughton, Loo, Dendukuri, Fenn, & Libman, 2009). 
Therefore, mechanical removal with soap and water was used when treating patients with CDI.  
To monitor hand hygiene compliance, random hospital-wide audits were conducted monthly on 
all employees.  Each time a healthcare employee (of any type) entered or exited a patient’s 
room, the auditor recorded whether or not they applied soap and water and/or alcohol-based 
hand gel.   
The second strategy is antibiotic stewardship.  In July of 2014, an antibiotic stewardship 
team, which primarily focused to minimize the inappropriate use of broad spectrum antibiotics, 
was implemented. Physician compliance to the program was of utmost importance.     
The third is preventing the transmission of C. difficile spores. Three methods have been 
implemented to curtail endospore transmission including: hand washing, isolation of positively 
screen C. difficile patients, and the use of disinfectants on the environmental surfaces. 
Asymptomatic patients with a history of C. Difficile are not put into isolation, but are screened 
for C. difficile.  For an asymptomatic patient to be put into isolation, they must have tested 
positive for C. Difficile.  Currently, this is an area of controversy, since some hospitals isolate 
patients based on history alone. In addition, an EPA-registered, quaternary ammonium-based, 
one step disinfectant with bactericidal properties, formulated to kill C. difficile spores, is used 
by environmental services at the hospital.    
C. Difficile Screening and Testing Methods 
 Our study used laboratory testing guidelines for C. difficile as outlined by The Society for 
Healthcare Epidemiology of America (SHEA) and The Infectious Disease Society of America 
(IDSA) (Cohen et al., 2010). Patients exhibiting three or more loose watery bowel movements 
(diarrhea) within a 24 hour period are tested for C. difficile. However, as part of a nursing 
protocol, asymptomatic patients with one loose bowel movement were often screened.  
 Two types of screening methods were used for identifying CDI; Toxin A and B Enzyme 
Immunoassay (toxin A/B EIA), and Polymerase Chain Reaction assays (PCR assays). Toxin A/B 
EIA test for the presence of C. difficile toxin A and toxin B in a patient’s stool sample. The run 
time for a single toxin A/B EIA can take between thirty minutes to two hours and up to 24 hours 
for a STAT C. difficile result.  We consider the toxin A/B EIA too insensitive to be used as the 
stand alone test to exclude CDIs. If a toxin A/B EIA yields a negative result, it is required to test 
the specimen two to three more times, which may increase the time to confirm a negative 
diagnosis to several days. For the average symptomatic patient, toxin A/B EIA screening is 
conducted three times to increase the test’s sensitivity. 
 In January of 2013, SOMC adopted PCR-based testing as the main CDI diagnosing 
method. PCR assays yield the highest sensitivity for detecting the presence of CDI through 
amplified DNA testing of the C. difficile toxin genes. PCR assays are significantly more rapid, 
taking approximately an hour to obtain a result with a 30% increase in sensitivity.  
 There are multiple testing algorithms that different hospitals and labs use for 
determining the presence of C. difficile in a stool. However, these algorithms were not used. 
PCR testing is only permitted on liquid stools and only one test every seven days, because a 
single stool specimen can rule out the presence of C. difficile. It is possible to detect C. difficile 
spores in the stool of patients who are just carrying C. difficile, and do not have a C. difficile 
associated disease. Thus, only symptomatic patients were tested with this method. If a 
specimen is not liquid, it is not tested, and thereby minimizes the risk of false positives. The 
only exception to this is when ileus is suspected in an asymptomatic patient.  
 Specimens that test positive must also be interpreted in the context of the patient’s 
history and presentation.  Nearly everyone who has C. difficile associated disease has a history 
of antibiotic usage in the past 3 months. This is important when deciding whether the onset of 
diarrhea is caused by C. difficile. “Test of cure” C. difficile PCR was not conducted, because 
lingering spores that would test as positive are possible even though the patient’s symptoms 
may have resolved. The only “test of cure” necessary for C. difficile is the resolution of 
symptoms.  
RESULTS 
Figure 1 
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Figure 1: The rate of C. Difficile infections per month from July 2011 to September 2015 at SOMC. The number of 
C. Difficile infection with hygiene protocol implementation in 2011, antibiotic stewardship program 
implementation in July 2014, and PCR screening method implementation in January 2013.     
 
Our results do not support improving C. difficile infection rates by hospital hand hygiene 
alone as the sole intervention. We found that since 2011, the overall CDI rate has increased 
tenfold (0.073% to 0.702%). During this time period, very few instances of a decreasing trend 
were observed. In addition, our data shows no reduction in C. difficile infection rates during 
implementation of antibiotic stewardship. However, the compliance of staff and physicians to 
both of the methods could be the cause for the lack of reduction in infection rates. 
Our results do support a significant increase in sensitivity for C. difficile testing using PCR 
assays (p < 0.05). This observation suggests that PCR-based testing for CDI diagnosis has a 
higher sensitivity for detecting the presence of C. difficile toxins compared to other methods 
and will result in a more accurate diagnosis of CDI. 
DISCUSSION  
 Placing alcohol-based hand antiseptics in easily-accessible areas of all units in the 
hospital is successful in improving hand hygiene compliance (John M. Boyce, 2000; Cookson et 
al., 2001). Alcohol-based hand antiseptics placed conveniently at the point of care allows 
healthcare employees to effectively reduce vegetative bacteria on their hands much faster. 
However, C. difficile spores negate these beneficial effects of alcohol-based hand antiseptics 
(Wullt, Odenholt, & Walder, 2003).  
 One could hypothesize that the absence of a relationship between CDI rates and 
hospital hand hygiene in our study is due to the mistaken use of alcohol-based antiseptics 
instead of mechanical hand washing. By eliminating competing bacteria in the facility’s 
microbiome, it is theoretically possible that this even promoted CDI (J. M. Boyce, Ligi, Kohan, 
Dumigan, & Havill, 2006; Horner, Mawer, & Wilcox, 2012; Jabbar et al., 2010; McFarland, 
Mulligan, Kwok, & Stamm, 1989). 
 PCR assays vs. toxin A/B EIA. There has been much debate on whether PCR assays or 
toxin A/B EIA are most effective in testing for C. difficile toxins. According to a recent study, 
approximately 90% of laboratories in the United States prefer toxin A/B EIA opposed to PCR, 
because they are easy to use and cost efficient (Johnson et al., 2001). However, toxin A/B EIA 
has been shown to lead to low negative predictive values leading to false-positive results, due 
to their low sensitivity (Gould & McDonald, 2009). As a result multiple tests are needed for a 
positive confirmation, which lengthens the time frame for diagnosis. 
 Generally, the majority of C. difficile colonized in a person exists as spores (McFarland et 
al., 1989). Since only one PCR assay needs to be run, eliminating a CDI diagnosis is much faster. 
It is beneficial to diagnosis patients early with CDI, so that treatment can begin before the 
spores germinate. However, the downside to this is the possibility of colonization causing a 
false positive in an uninfected patient with loose bowel movements. This was prevented by 
only permitting PCR assays to symptomatic patients. If the stool specimen is not liquid, it was 
not tested. 
 The CDC has indicated that PCR is “too sensitive”, postulating that it detects colonization 
within the organism, instead of the disease itself. An accompanying commentary stated that up 
to 15% of hospitalized patients are colonized with C. difficile, but is the etiological agent of 
diarrhea in only 5-10% of them. This suggests that the low positive predictive value of PCR 
assays (44.7%) translates into false positives for infectious disease, and emphasizes the 
importance of analyzing patient history with the test results.  
 After the antibiotic stewardship team’s implementation, the first decreasing trend in CDI 
rates (-0.07% from January-June 2015) since PCR assays were in place was observed. Dancer, et 
al., have observed that an antibiotic stewardship program restricting the use of ciprofloxacin 
and ceftriaxone can reduce CDI by over 70% (Dancer et al., 2013). Our program restricted the 
use of several antimicrobials; however, we did not see an overall trend in reduction. 
 The antimicrobial stewardship team placed a strong focus on thoroughly educating the 
physicians and promoting their compliance. They provided a selection of lower risk 
antimicrobials (for other infections) when possible, and encouraged avoiding antibiotics unless 
an indicated condition was present. It was found that an effective antibiotic stewardship 
initiative is essential to slowing the incidence of CDI.  
 Prior data suggests that 30-50% of all hospitalized patients receive some kind of 
antimicrobial/antibiotic treatment (Metjian, Prasad, Kogon, Coffin, & Zaoutis, 2008). The use of 
antibiotics in over 50% of cases in the United States was deemed unnecessary and/or 
inappropriate (Fishman, 2006). Since most cases of CDI occur in patients previously exposed to 
prolonged cycles of antibiotics, this poses a serious threat for CDI.  
 As part of the antibiotic stewardship program, a semi-annual antibiogram was put in 
place to monitor the use of antibiotics. This provides statistics of what antibiotics are effective 
against different organisms, and provides information on narrow spectrum drugs for those 
organisms. It has been shown that increasing the duration of patient exposure to antimicrobials 
increases the risk of resistant organisms colonizing (McGowan, 1983). The antibiogram assists in 
preventing the overuse of broad-spectrum drugs, while preserving the effectiveness of the 
antibiotics available. Over usage of antibiotics puts a selective pressure on microorganisms to 
develop resistance, so by using the antibiogram a physician can select the appropriate antibiotic 
to alleviate an infection.  
 The goal of an antibiotic/antimicrobial stewardship program is to treat all patients with 
the appropriate antibiotic that is both cost effective and of least toxicity, while optimizing its 
dosage, duration of treatment, and de-escalation in order to help prevent the spread of 
infection (Fishman, 2006; Piacenti & Leuthner, 2013; Shlaes et al., 1997). It is crucial that we 
control and monitor specific antibiotic usage throughout the hospital by integrating hospital 
guidelines, staff education, and enforcement of infection control policies (Piacenti & Leuthner, 
2013). In several hospitals that placed restrictions on antimicrobials, similar to our study, a 
reduction in both the incidence and prevalence of resistant organisms was observed 
(Bamberger & Dahl, 1992; Berk, Alvarez, Ortega, Verghese, & Holtsclaw-Berk, 1986; BETTS et 
al., 1984; D. Gerding et al., 1991; King, White, Todd, & Conrad, 1992; McGowan, 1994; Pear, 
Williamson, Bettin, Gerding, & Galgiani, 1994; Van Landuyt, Boelaert, Glibert, Gordts, & 
Verbruggen, 1986; YOUNG, SEWELL, KOZA, & CLARRIDGE, 1985). In another study, the 
incorporation of an antibiotic stewardship program was shown to significantly decrease the 
rates of selected nosocomial infections (Frank et al., 1996). 
 Recently, C. difficile-associated diarrhea has posed major threat to patients prescribed 
antibiotics, deeming it more a public health concern than antimicrobial resistance (Piacenti & 
Leuthner, 2013). In a secondary/tertiary-care hospital in Quebec, an interrupted time-series 
analysis studied the influence a nonrestrictive antibiotic stewardship program had on the 
incidence of nosocomial C. difficile-associated disease during an epidemic. They found from 
2003-2004 to 2005-2006, total and targeted antibiotic usage decreased by 23% and 54%, 
respectively, and a 60% decrease in the incidence of nosocomial C. difficile associated disease 
was observed (Valiquette, Cossette, Garant, Diab, & Pépin, 2007). In a similar study that 
evaluated the impact of antibiotic stewardship focused on high-risk antibiotics, they found a 
borderline significant reduction in high-risk antibiotic usage associated with a significant 
reduction in the CDI rate by 0.0047/100 bed days per month (M. A. Aldeyab et al., 2012). In 
several other published studies, antibiotic stewardship programs have demonstrated to be 
highly successful in the improvement of patient outcomes, reducing CDIs in hospital settings, 
and reducing readmission rates (Bishop, Parry, & Hall, 2013; Dortch et al., 2011; Fridkin & 
Srinivasan, 2013; Goff et al., 2012; Malani et al., 2013; Pasquale et al., 2014; Yong, Buising, 
Cheng, & Thursky, 2010). 
 All things considered, when faced with the current crisis of the emerging incidences of 
CDIs and C. difficile associated diseases amongst hospitals, our data shows no improvement in 
infection rates with hand hygiene and antibiotic stewardship programs. Despite these odds, 
infectious disease specialists still highly recommended that hospitals incorporate similar 
prevention strategies based off of the results of other studies (Goldstein et al., 2015). However, 
our results do suggest PCR assays should be used to screen and diagnose C. difficile infections in 
patients. Utilizing PCR screening methods which provide quick and accurate results may help 
prevent the spread of C. difficile between patients. 
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